Reversing Skeletal Muscle Myopathy by Hydrogen Sulfide

硫化氢逆转骨骼肌肌病

基本信息

  • 批准号:
    10089145
  • 负责人:
  • 金额:
    $ 32.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-21 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

Children born with severe homocystinuria due to homozygous cystathionine beta synthase deficiency (CBS-/-) exhibit poor body weights, skeletal muscle myopathy and die in teenage. Although mice with homozygous CBS mutation die shortly after birth, the heterozygous CBS-/+ survives. Our preliminary data suggests that enzymes, CBS and cystathionine gamma-lyase (CSE) that irreversibly remove homocysteine (Hcy) by converting to hydrogen sulfide (H2S), are decreased in skeletal muscle. Although lowering of Hcy levels and generation of H2S is beneficial, the mechanism by which HHcy causes of skeletal muscle wasting and frailty is unknown. The long-term goal of this project is to understand the mechanism of muscle wasting in HHcy and evaluate the potential beneficial effects of H2S signaling in reversing skeletal muscle wasting and myopathy. The central hypothesis of this proposal is that HHcy causes skeletal muscle deterioration by compromising vasculogenesis, by enhancing muscle atrophy and by limiting skeletal muscle regeneration and H2S reverses these changes. We will test this hypothesis by following three specific aims: Specific Aim #1: To determine whether the HHcy inhibits muscle specific AKT, HIF-1, and AMPK signaling and impairs vasculogenesis and H2S reverses impaired vasculogenesis. Specific Aim #2: To determine whether the HHcy attenuates PGC-1 signaling and instigates atrogene expression and causes muscular atrophy and H2S mitigates muscle atrophy. Specific Aim #3: To determine whether the HHcy enhances TGF-1 signaling and myostatin levels, thereby suppresses muscle regeneration and H2S ameliorates these changes.
由于纯合型胱硫醚β合酶缺乏症(CBS-/-)而患有严重同型胱氨酸尿症的儿童 表现出体重不足、骨骼肌肌病并在青少年时期死亡。尽管携带纯合子CBS的小鼠 突变在出生后不久死亡,杂合子CBS-/+存活。我们的初步数据显示, 酶,CBS和胱硫醚γ-裂解酶(CSE),通过 转化为硫化氢(H2S),在骨骼肌中减少。虽然降低Hcy水平, H2S的产生是有益的,HHcy导致骨骼肌消耗和脆弱的机制是 未知本项目的长期目标是了解高同型半胱氨酸引起肌肉萎缩的机制, 评估H2S信号在逆转骨骼肌萎缩和肌病中的潜在有益作用。 该建议的中心假设是,HHcy通过以下方式引起骨骼肌退化: 通过促进肌肉萎缩和限制骨骼肌, 再生和H2S逆转了这些变化。我们将通过以下三个具体目标来检验这一假设: 具体目标#1:确定HHcy是否抑制肌肉特异性AKT、HIF-1和AMPK 信号传导并损害血管发生,H2S逆转受损的血管发生。 具体目标#2:确定HHcy是否减弱PGC-1信号传导并刺激萎缩性细胞因子 H2S表达并引起肌肉萎缩,H2S减轻肌肉萎缩。 具体目标#3:为了确定HHCy是否增强TGF-β 1信号传导和肌肉生长抑制素水平, 从而抑制肌肉再生,H2S改善这些变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Suresh C. Tyagi其他文献

Vascular Health and Risk Management Dovepress Dovepress Blood Flow Interplays with Elastin: Collagen and Mmp: Timp Ratios to Maintain Healthy Vascular Structure and Function
血管健康和风险管理 Dovepress Dovepress 血流与弹性蛋白:胶原蛋白和 Mmp:维持健康血管结构和功能的 Timp 比率相互作用
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Poulami Basu;U. Sen;N. Tyagi;Suresh C. Tyagi
  • 通讯作者:
    Suresh C. Tyagi
Porphyromonas gingivalis induces cardiovascular dysfunction.
牙龈卟啉单胞菌会诱发心血管功能障碍。
  • DOI:
    10.1139/cjpp-2022-0392
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Dragana Stanisic;N. Jeremić;Mahavir Singh;S. Pushpakumar;S. Mokshagundam;Suresh C. Tyagi
  • 通讯作者:
    Suresh C. Tyagi
Dynamic role of extracellular matrix metalloproteinases in heart failure.
Autophagy and Heart Failure: A Possible Role for Homocysteine
自噬与心力衰竭:同型半胱氨酸的可能作用
  • DOI:
    10.1007/s12013-011-9281-6
  • 发表时间:
    2011-09-11
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Thomas P. Vacek;Jonathan C. Vacek;Neetu Tyagi;Suresh C. Tyagi
  • 通讯作者:
    Suresh C. Tyagi
Exosomes: cell-created drug delivery systems
  • DOI:
    10.1007/s11010-019-03545-4
  • 发表时间:
    2019-05-09
  • 期刊:
  • 影响因子:
    3.700
  • 作者:
    Anastasia Familtseva;Nevena Jeremic;Suresh C. Tyagi
  • 通讯作者:
    Suresh C. Tyagi

Suresh C. Tyagi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Suresh C. Tyagi', 18)}}的其他基金

Remote Hind Limb Ischemia Mechanism of Cardioprotection
远距离后肢缺血的心脏保护机制
  • 批准号:
    10247852
  • 财政年份:
    2020
  • 资助金额:
    $ 32.86万
  • 项目类别:
Reversing Skeletal Muscle Myopathy by Hydrogen Sulfide
硫化氢逆转骨骼肌肌病
  • 批准号:
    10557832
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
Remote Hind Limb Ischemia Mechanism of Cardioprotection
远距离后肢缺血的心脏保护机制
  • 批准号:
    10215605
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
Remote Hind Limb Ischemia Mechanism of Cardioprotection
远距离后肢缺血的心脏保护机制
  • 批准号:
    10438112
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
Reversing Skeletal Muscle Myopathy by Hydrogen Sulfide
硫化氢逆转骨骼肌肌病
  • 批准号:
    10357570
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
Mitophagic and anti-angiogenic mechanism of heart failure
心力衰竭的线粒体自噬和抗血管生成机制
  • 批准号:
    8600989
  • 财政年份:
    2011
  • 资助金额:
    $ 32.86万
  • 项目类别:
Mitophagic and anti-angiogenic mechanism of heart failure
心力衰竭的线粒体自噬和抗血管生成机制
  • 批准号:
    8131312
  • 财政年份:
    2011
  • 资助金额:
    $ 32.86万
  • 项目类别:
Mitophagic and anti-angiogenic mechanism of heart failure
心力衰竭的线粒体自噬和抗血管生成机制
  • 批准号:
    8258238
  • 财政年份:
    2011
  • 资助金额:
    $ 32.86万
  • 项目类别:
Mitophagic and anti-angiogenic mechanism of heart failure
心力衰竭的线粒体自噬和抗血管生成机制
  • 批准号:
    8403722
  • 财政年份:
    2011
  • 资助金额:
    $ 32.86万
  • 项目类别:
Implications of Endothelial-Myocyte Uncoupling in Cardiac Arrhythmia
内皮-肌细胞解偶联对心律失常的影响
  • 批准号:
    7408062
  • 财政年份:
    2007
  • 资助金额:
    $ 32.86万
  • 项目类别:

相似海外基金

Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
  • 批准号:
    10635325
  • 财政年份:
    2023
  • 资助金额:
    $ 32.86万
  • 项目类别:
In vivo Identification of Pre-Atrophic Brain Neurodegeneration in Prodromal Alzheimer Disease with Quantitative Gradient Recalled Echo MRI
利用定量梯度回忆回波 MRI 体内鉴定阿尔茨海默病前驱期的萎缩前脑神经变性
  • 批准号:
    10448152
  • 财政年份:
    2022
  • 资助金额:
    $ 32.86万
  • 项目类别:
The Development and Rescue of an Atrophic Nonunion Model
萎缩性骨不连模型的开发和挽救
  • 批准号:
    10007577
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
The Development and Rescue of an Atrophic Nonunion Model
萎缩性骨不连模型的开发和挽救
  • 批准号:
    10242918
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Analysis of the role of AMPK in the retina for the development of a novel treatment for atrophic age-related macular degeneration
分析 AMPK 在视网膜中的作用,以开发治疗萎缩性年龄相关性黄斑变性的新方法
  • 批准号:
    18K09457
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regeneration of atrophic salivary glands by reconstructing tissue macrophages using amniotic fluid-derived cells
利用羊水来源的细胞重建组织巨噬细胞来再生萎缩的唾液腺
  • 批准号:
    19K21370
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
The study to detect early-stage pancreatic cancer based on the data from molecular biology about the atrophic acinar cell surrounding carcinoma in situ.
该研究基于原位癌周围萎缩性腺泡细胞的分子生物学数据来检测早期胰腺癌。
  • 批准号:
    18K07897
  • 财政年份:
    2018
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multiple control and visualization of self-somatic- stem cells for atrophic jaw bone augmentation
用于萎缩颌骨增量的自体干细胞的多重控制和可视化
  • 批准号:
    17H04394
  • 财政年份:
    2017
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Delivery of concentrated peripheral blood derived EPCs and functional miRNAs for atrophic salivary gland regeneration
输送浓缩的外周血来源的 EPC 和功能性 miRNA 以促进萎缩唾液腺再生
  • 批准号:
    17K17272
  • 财政年份:
    2017
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of novel oligonucleotide therapeutics using functional liposomes for atrophic muscular disorder
使用功能性脂质体开发治疗萎缩性肌肉疾病的新型寡核苷酸疗法
  • 批准号:
    16K20646
  • 财政年份:
    2016
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了